BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 35693786)

  • 1. A Machine-Learning Approach to Developing a Predictive Signature Based on Transcriptome Profiling of Ground-Glass Opacities for Accurate Classification and Exploring the Immune Microenvironment of Early-Stage LUAD.
    Zhao Z; Yin W; Peng X; Cai Q; He B; Shi S; Peng W; Tu G; Li Y; Li D; Tao Y; Peng M; Wang X; Yu F
    Front Immunol; 2022; 13():872387. PubMed ID: 35693786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
    Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.
    Bao X; Shi R; Zhao T; Wang Y
    J Mol Med (Berl); 2020 Jun; 98(6):805-818. PubMed ID: 32333046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel transcriptomic signature associated with lymphovascular invasion predicts clinical outcomes, tumor microenvironment, and therapeutic response in lung adenocarcinoma.
    Huang X; Feng Y; Li Y; Ding H; Huang X; Chen C; Yu Z; Zhang J; Xu X; Ma D; Yu S; Chen C
    Int Immunopharmacol; 2024 Jan; 127():111286. PubMed ID: 38064818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-cell sequencing analysis and transcriptome analysis constructed the macrophage related gene-related signature in lung adenocarcinoma and verified by an independent cohort.
    Li R; Tong R; Zhang Z; Deng M; Wang T; Hou G
    Genomics; 2022 Nov; 114(6):110520. PubMed ID: 36372305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of a Machine Learning Prognostic Model of m5C Related immune Genes in Lung Adenocarcinoma.
    Cao X; Ji Y; Li J; Liu Z; Chen C
    Cancer Control; 2024; 31():10732748241237414. PubMed ID: 38537151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel ferroptosis-related genes model for prognosis prediction of lung adenocarcinoma.
    Li F; Ge D; Sun SL
    BMC Pulm Med; 2021 Jul; 21(1):229. PubMed ID: 34256754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six CT83-related Genes-based Prognostic Signature for Lung Adenocarcinoma.
    Wang Y; Zhang G; Wang R
    Comb Chem High Throughput Screen; 2022; 25(9):1565-1575. PubMed ID: 34259140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-related gene signature for predicting LUAD patients' prognosis and immune microenvironment.
    Chen J; Fu Y; Hu J; He J
    Cytokine; 2022 Apr; 152():155820. PubMed ID: 35176657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
    Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
    Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
    Shu J; Jiang J; Zhao G
    Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
    Chen G; Dong Z; Wu D; Chen Y
    J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and analysis of a novel ferroptosis-related gene signature predicting prognosis in lung adenocarcinoma.
    Zhou J; Wang X; Li Z; Jiang R
    FEBS Open Bio; 2021 Nov; 11(11):3005-3018. PubMed ID: 34499810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.
    Song P; Li W; Wu X; Qian Z; Ying J; Gao S; He J
    Cancer Immunol Immunother; 2022 Oct; 71(10):2341-2354. PubMed ID: 35152302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.